Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
По алфавиту
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- L
- M
- N
- O
- P
- Q
- R
- S
- T
- V
- W
- X
- Y
- Z
- І
- А
- Б
- В
- Г
- Д
- Е
- Ж
- З
- И
- К
- Л
- М
- Н
- О
- П
- Р
- С
- Т
- У
- Ф
- Х
- Ц
- Ч
- Ш
- Щ
- Э
- Ю
- Я
- Весь список
Warning: mb_strpos(): Empty delimiter in /var/www/u1363561/data/www/biotech.spb.ru/wp-content/plugins/code-snippets/php/snippet-ops.php(581) : eval()’d code(4) : eval()’d code on line 13
P A Palmer, J Atzpodien, T Philip, S Negrier, H Kirchner, H Von der Maase, P Geertsen, P Evers, E Loriaux, R Oskam, et al.
A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinomaCancer Biother. Summer 1993;8(2):123-36.
P J Gold, J A Thompson, D R Markowitz, S Neumann, A Fefer
Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2Cancer J Sci Am. 1997 Dec;3 Suppl 1:S85-91.
P M Anderson, E Katsanis, S F Sencer, D Hasz, A C Ochoa, B Bostrom
Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administrationJ Immunother (1991). 1992 Jul;12(1):19-31.
P M Anderson, M A Sorenson
Effects of route and formulation on clinical pharmacokinetics of interleukin-2Clin Pharmacokinet. 1994 Jul;27(1):19-31.
Papa MZ, Mulé JJ, Rosenberg SA.
Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.Cancer Res. 1986 Oct;46(10):4973-8. PMID: 3489517.
Parkinson DR.
Lessons from the clinical trials of interleukin-2.Nat Immun Cell Growth Regul. 1990;9(4):242-52. PMID: 2215513.
Parkinson DR.
The role of interleukin-2 in the biotherapy of cancer.Oncol Nurs Forum. 1989 Nov-Dec;16(6 Suppl):16-20. PMID: 2687810.
Parra M, Herrera D, Jácome MF et al.
Circulating rotavirus-specific T cells have a poor functional profile.Virology. 2014 Nov;468-470:340-350.
Pautas C, Merabet F, Thomas X et al.
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 studyJ Clin Oncol. 2010 Feb 10;28(5):808-14.
Pavone L., Fanti G., Bongiovanni C. et al.
Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.Med Oncol. 2009;26(1):38-44. doi: 10.1007/s12032-008-9078-7. Epub 2008 May 31.
Petra Votavova, Jakub Tomala, Marek Kovar
Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimeraImmunol Lett. May-Jun 2014;159(1-2):1-10.
Petrov S.V., Bubnova N.A., Prokofyeva M.V. et al.
Postoperative immunotherapy with IL-2 (Roncoleukin®) in patients with severe peritonitis.
Abstacts book of 5th Sci. Meeting of Europ. Soc. of chemotherapy inf. diseases. S.-Petersburg, 1997. P. 55 (R002).
Petrov S.V., Totolyan A.A., Bubnova N.A. et al.
Clinical and immunological effects of IL-2 (RONCOLEUKIN) in patients with surgical sepsis. Results of double -blind study.
Abstacts book of 5th Sci. Meeting of Europ. Soc. of chemotherapy inf. diseases. S.-Petersburg, 1997. P. 54 (R002).
Petrulio C.A., DeRaffele G., Kaufman H.L.
High Dose Interleukin-2 Therapy.General Principles of Tumor Immunotherapy (pp.431-452). — January 2008.
Pett SL, Carey C, Lin E et al.
Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).HIV Med. 2011 Apr;12(4):219-27.
Pett SL, Kelleher AD, Emery S.
Role of interleukin-2 in patients with HIV infection.Drugs. 2010 Jun 18;70(9):1115-30.
Pooja Dhupkar, Nancy Gordon
Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic EfficacyAdv Exp Med Biol. 2017;995:33-51.
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.